SCHEMBL5518205

SCHEMBL5518205

CCN(CC)CCOc1ccc(Nc2ncc3nc(-c4cc(OC)cc(OC)c4)c(=O)n(CC)c3n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 4/20 0.63
CCND1 P24385 4/20 0.63
CCND2 P30279 4/20 0.63
CCND3 P30281 4/20 0.63
RIPK2 O43353 8/20 0.62
NOD2 Q9HC29 8/20 0.62
ACVR1 Q04771 6/20 0.62
FGFR1 P11362 1/20 0.58
USP2 O75604 5/20 0.55
CASP1 P29466 5/20 0.55
CASP7 P55210 5/20 0.55
CYP2C9 P11712 1/20 0.55
HIF1A Q16665 1/20 0.55
MEN1 O00255 4/20 0.53
CYP1A2 P05177 4/20 0.53
KMT2A Q03164 4/20 0.53
BRCA1 P38398 3/20 0.53
CYP3A4 P08684 2/20 0.53
HBB P68871 2/20 0.53
SRC P12931 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5519282 0.84 FGFR1 (0.66) CDK4CCND1CCND2CCND3FGFR1
SCHEMBL5520426 0.80 RIPK2 (0.73) RIPK2NOD2ACVR1FGFR1USP2
SCHEMBL3972205 0.80 CDK4 (0.60) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5516556 0.79 RIPK2 (0.53) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL4353287 0.78 CDK4 (1.00) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL20563559 0.77 RIPK2 (1.00) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL4679629 0.76 RIPK2 (0.66) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5520692 0.76 RIPK2 (0.62) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL4676705 0.75 FGFR1 (0.55) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL20564685 0.75 RIPK2 (1.00) RIPK2NOD2ACVR1FGFR1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US claimed
EP-1409487-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-04-21 EP claimed
US-20030130286-A1 Pteridinones as kinase inhibitors DENNY WILLIAM ALEXANDER (NZ) 2003-07-10 US claimed
WO-2001019825-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-03-22 WO claimed
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US disclosed
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US disclosed
US-20030130286-A1 Pteridinones as kinase inhibitors DENNY WILLIAM ALEXANDER (NZ) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130286-A1 Pteridinones as kinase inhibitors CCNI, CCNK, CDK2 CDK4 5/4885CCND1 32/4885CCND2 31/4885
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS CCNI, CCNK, CDK2 CDK4 5/4885CCND1 21/4885CCND2 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.